Pulsed dye laser treatment of pigmented lesions: a randomized clinical pilot study comparison of 607- and 595-nm wavelength lasers

✍ Scribed by Peggy L. Chern; Yacov Domankevitz; E. Victor Ross

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 285 KB
• Volume: 42
• Category: Article
• ISSN: 0196-8092
• DOI: 10.1002/lsm.20982

✦ Synopsis

Abstract

Background

The 595‐nm pulsed dye laser has been used for the treatment of benign epidermal pigmented lesions (EPLs), but there is a risk of inducing undesirable purpura with treatment.

Objective

To compare a 607‐nm laser with a commercially‐available 595‐nm laser for the treatment of EPLs.

Materials and Methods

Monte‐Carlo simulations were performed to characterize laser interaction with skin. Ten patients with EPLs were treated with a 607‐nm study prototype laser and the 595‐nm pulsed dye laser twice at 2‐ to 4‐week intervals on the left or right side on a randomized basis. Study endpoints included clearance rate of lesions, side effects immediately after treatment and at final follow‐up, and patient discomfort/pain.

Results

Monte‐Carlo simulations show that the 607‐nm is absorbed more specifically by melanin than the 595‐nm wavelength. Both lasers were effective in treatment of EPLs. The average degree of improvement overall was 41.2% with the 607‐nm laser and 40% with the 595‐nm laser. Patients reported less discomfort/pain during treatment with the 607‐nm laser.

Conclusions

Our findings suggest that the 607‐nm laser is safe and at least as effective as the 595‐nm laser in treatment of EPLs. There was less patient discomfort/pain during treatment using the 607‐nm laser. Lasers Surg. Med. 42:865–869, 2010. © 2010 Wiley‐Liss, Inc.